Madrigal Pharmaceuticals (MDGL) Earnings Date, Estimates & Call Transcripts $308.44 +15.03 (+5.12%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Madrigal Pharmaceuticals Latest Earnings SummaryActual EPS (Oct. 31) -$4.92 Beat By $2.02 Consensus EPS (Oct. 31) -$6.94 Madrigal Pharmaceuticals posted Q3 2024 earnings on October 31, 2024, reporting an EPS of -$4.92, which topped analysts' consensus estimates of -$6.94 by $2.02. Quarterly revenue was reported to be $62.18 million, above analyst estimates of $34.60 million. With a trailing EPS of -$25.08, Madrigal Pharmaceuticals' earnings are expected to grow next year, from ($23.77) to ($13.08) per share. Conference CallConference Call TranscriptPowered by Get Madrigal Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Madrigal Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataMDGL Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.MDGL Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Madrigal Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243-$6.66-$5.82-$6.17Q2 20243-$8.36-$5.63-$7.16Q3 20243-$8.45-$4.91-$6.70Q4 20243-$6.18-$3.22-$4.42FY 202412-$29.65-$19.58-$24.44Q1 20251-$3.34-$3.34-$3.34Q2 20251-$3.09-$3.09-$3.09Q3 20251-$2.86-$2.86-$2.86Q4 20251-$2.46-$2.46-$2.46FY 20254($11.75)($11.75)($11.75) Madrigal Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails10/31/2024Q3 2024-$6.94-$4.92+$2.02-$4.92$34.60M$62.18M8/7/2024Q2 2024-$7.55-$7.10+$0.45-$7.10$4.25M$14.64M5/7/2024Q1 2024-$6.06-$7.38 -$1.32-$7.38--2/28/2024Q4 2023-$5.26-$5.68 -$0.42-$5.68--11/6/2023Q3 2023-$4.90-$5.34 -$0.44-$5.34--8/8/2023Q2 2023-$4.59-$4.69 -$0.10-$4.69--Your bank is lying to you. (Ad)You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.View the best savings account rates here5/9/2023Q1 2023-$4.78-$4.23+$0.55-$4.23--2/23/2023Q4 2022-$4.61-$4.98 -$0.37-$4.98-- Madrigal Pharmaceuticals Earnings - Frequently Asked Questions When did Madrigal Pharmaceuticals announce their last quarterly earnings? Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earning data on Thursday, October 31, 2024. Learn more on MDGL's earnings history. Did Madrigal Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Madrigal Pharmaceuticals (NASDAQ:MDGL) reported ($4.92) earnings per share (EPS) to beat the analysts' consensus estimate of ($6.94) by $2.02. Learn more on analysts' earnings estimate vs. MDGL's actual earnings. How can I listen to Madrigal Pharmaceuticals's earnings conference call? The conference call for Madrigal Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Madrigal Pharmaceuticals's conference call transcript? The conference call transcript for Madrigal Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Madrigal Pharmaceuticals generate each year? Madrigal Pharmaceuticals (NASDAQ:MDGL) has a recorded annual revenue of $76.81 million. How much profit does Madrigal Pharmaceuticals generate each year? Madrigal Pharmaceuticals (NASDAQ:MDGL) has a recorded net income of -$373.63 million. MDGL has generated -$25.08 earnings per share over the last four quarters. What is Madrigal Pharmaceuticals's EPS forecast for next year? Madrigal Pharmaceuticals's earnings are expected to grow from ($23.77) per share to ($13.08) per share in the next year. More Earnings Resources from MarketBeat Related Companies BIIB Earnings Date UTHR Earnings Date NBIX Earnings Date INCY Earnings Date BMRN Earnings Date EXAS Earnings Date EXEL Earnings Date RGEN Earnings Date HALO Earnings Date IONS Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings 70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << This page (NASDAQ:MDGL) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
